Eyenovia, Inc. (EYEN)
NASDAQ: EYEN · IEX Real-Time Price · USD
0.571
+0.040 (7.48%)
At close: Apr 19, 2024, 4:00 PM
0.560
-0.011 (-1.88%)
After-hours: Apr 19, 2024, 7:59 PM EDT

Company Description

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology.

The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.

It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi.

The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014.

Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Eyenovia, Inc.
Eyenovia logo
Country United States
Founded 2014
IPO Date Jan 25, 2018
Industry Biotechnology
Sector Healthcare
Employees 57
CEO Michael M. Rowe

Contact Details

Address:
295 Madison Avenue, Suite 2400
New York, New York 10017
United States
Phone 813-766-9539
Website eyenovia.com

Stock Details

Ticker Symbol EYEN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001682639
CUSIP Number 30234E104
ISIN Number US30234E1047
Employer ID 47-1178401
SIC Code 2834

Key Executives

Name Position
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH Co-Founder and Executive Chairman
Michael M. Rowe Chief Executive Officer and Director
John P. Gandolfo CPA Chief Financial Officer and Secretary
Bren Kern Chief Operating Officer and Corporate Vice President
Alexander Lobo Investor Contact

Latest SEC Filings

Date Type Title
Apr 10, 2024 8-K Current Report
Apr 10, 2024 424B5 Filing
Apr 9, 2024 8-K Current Report
Apr 8, 2024 8-K Current Report
Mar 19, 2024 8-K Current Report
Mar 18, 2024 10-K Annual Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 8-K/A [Amend] Current report
Jan 25, 2024 8-K Current Report
Jan 16, 2024 8-K Current Report